Array BioPharma appoints vp of clinical development
Bengt Berstrom has joined biopharmaceutical firm Array BioPharma as vp of clinical development.
With more than 17 years" working in the pharmaceutical industry, Dr Bergstrom will lead Array's clinical science and drug safety activities for its growing pipeline of targeted small molecule drugs to treat cancer and inflammatory diseases.
"Bengt's expertise in advancing cancer and inflammation therapeutics, including oral cancer therapies such as Xeloda, will be a competitive advantage for Array as we progress our five wholly owned drugs in human clinical development," said chief executive Robert Conway.
Prior to joining Array, Dr Bergstrom held various roles Hoffmann-La Roche, most recently as clinical science leader in oncology drug development.
Dr Bergstrom studied at the University of Lund in Sweden where he received his MD and PhD.
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027